Curtana neurons

Curtana Pharmaceuticals

First Targeted Small Molecule Therapeutics for the Treatment of Glioblastoma and Other Brain Cancers

  • Stage Product In Development
  • Industry Biotechnology
  • Location Austin, TX, US
  • Currency USD
  • Founded April 2013
  • Employees 5
  • Incorporation Type C-corp
  • Website

Company Summary

Curtana Pharmaceuticals is a privately-held, preclinical-stage biotech company developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system (CNS) for the treatment of glioblastoma (GBM) and other brain cancers, which is a $1 billion world-wide market opportunity. There remains significant unmet clinical need in the GBM market as the median survival is less than 15 months.


  • Photo
    President and CEO

    Dr. Stein co-founded Curtana Pharmaceuticals and became the company’s Chief Executive Officer in April, 2013. During his professional career of over 20 years, he has been a clinician and a life sciences executive with experience in the areas of diagnostics, medical devices, pharmaceuticals and biotechnology.

  • Default avatar
    Graham Beaton, PhD
    VP, Medicinal Chemistry and Drug Discovery

    Dr. Graham Beaton serves as VP, Medicinal Chemistry and Drug Discovery. He has the expertise, leadership and motivation necessary to successfully carry out the mission required for a start-up pharmaceutical company. Dr. Beaton has over 22 years of experience in industrial science. He brings significant experience in all aspects of drug discovery, including medicinal chemistry, program management and organic synthesis.

  • Default avatar
    Gordon Alton, PhD
    VP, Research and Development

    Dr. Gordon Alton currently serves as Vice President of Research and Development. He has more than 19 years of structure-based drug discovery experience in oncology, inflammation, metabolic disease, CNS diseases and ophthalmology. He has deep knowledge of signal transduction, kinases, nuclear receptors, GPCRs, and metabolic enzymes. He has importantly contributed to the successful development of multiple drugs, clinical candidates and INDs.